DRTSW (DRTSW) Stock Price & Analysis
DRTSW (DRTSW) rose 3.60% to USD 1.87 as of June 10, 2026 at 15:35 UTC, according to Nexqual real-time market data.
DRTSW last closed at USD 1.81; the session ranged USD 1.85–1.87 on volume of 938 shares. Market capitalization is —, with a 52-week range of USD 1.85–1.87 (NCM). Source: Nexqual, June 10, 2026 at 15:35 UTC.
Key Statistics (as of June 10, 2026 at 15:35 UTC)
| Price | USD 1.87 |
|---|---|
| Change | ▲ 3.60% (up) |
| Previous Close | USD 1.81 |
| Open | USD 0.33 |
| Day Range | USD 1.85 – 1.87 |
| 52-Week Range | USD 1.85 – 1.87 |
| Volume | 938 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (DRTSW)
Nexqual's technical model rates DRTSW "BUY" based on 5 bullish and 3 bearish signals across 67 daily candles, as of June 10, 2026 at 15:35 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Above (USD 1.04) |
| MACD | 0.07 (positive) |
Analyst Ratings (DRTSW)
Wall Street analysts rate DRTSW "None", per Nexqual as of June 10, 2026 at 15:35 UTC.
| Consensus Rating | None |
|---|
Earnings (DRTSW)
| Revenue Estimate | $192,670 |
|---|
Source: Nexqual, June 10, 2026 at 15:35 UTC.
Financials & Fundamentals (DRTSW)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -90.51% |
| Debt / Equity | 20.68 |
| Current Ratio | 7.79 |
| Total Cash | $76.42M |
| Total Debt | $14.34M |
Source: Nexqual, June 10, 2026 at 15:35 UTC.
Financial Health Score (DRTSW)
Nexqual rates DRTSW's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 15:35 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $76M cash vs $14M debt, net cash position |
| Cash Flow | Mixed — No data |
| Efficiency | Critical — ROE -91%, ROA -30.5% |
Ownership (DRTSW)
| Float | 61.83M |
|---|
Source: Nexqual, June 10, 2026 at 15:35 UTC.
Leadership (DRTSW)
DRTSW is led by Uzi Sofer (age 55), CEO & Chairman, per Nexqual as of June 10, 2026 at 15:35 UTC.
| CEO & Chairman | Uzi Sofer (age 55) |
|---|---|
| Chief Financial Officer | Raphi Levy (age 40) |
| Chief Technology Officer | Ronen Segal (age 52) |
| Chief Scientific Officer & Member of Scientific Advisory board | Yona Keisari (age 78) |
| Vice President of legal | Rebecca Becker |
Major Backers & Investors (DRTSW)
Notable institutional backers of DRTSW include Aristeia Capital, LLC, MMCAP International, Inc. SPC, LMR Partners LLP, according to Nexqual as of June 10, 2026 at 15:35 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Aristeia Capital, LLC | 2.32% |
| MMCAP International, Inc. SPC | 1.91% |
| LMR Partners LLP | 1.75% |
| Moore Capital Management, LP | 0.75% |
| Value Base Ltd. | 0.65% |
| Tenor Capital Management Co., L.p. | 0.64% |
| Whitebox Advisors, LLC | 0.58% |
| Wolverine Asset Management, LLC | 0.55% |
Source: Nexqual, June 10, 2026 at 15:35 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| DRTS | Alpha Tau Medical Ltd. | USD 9.27 | ▼ 0.16% |
| DRMAW | Dermata Therapeutics, Inc. Warrant | USD 0.01 | ▼ 19.67% |
| CINGW | Cingulate Inc. Warrants | USD 0.02 | ▼ 69.38% |
| REVBW | Revelation Biosciences, Inc. | USD 0.01 | ▲ 24.18% |
| CELUW | Celularity Inc. | USD 0 | ▼ 51.72% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 15:35 UTC. This page is informational and not investment advice.